

ARTRYA™

Coronary Artery Disease. We see you.

ASX ANNOUNCEMENT

8 April 2022

RELEASE OF SHARES FROM ESCROW

Artificial intelligence medical technology company, Artrya Limited (ASX: AYA, **Artrya** or the **Company**) advises that in accordance with ASX Listing Rule 3.10A, a total of 5,776,095 fully paid ordinary shares (**Shares**) will be released from escrow (**Escrowed Shares**).

Number of Shares	Release Date
5,183,961 Shares	19 April 2022
592,134 Shares	23 April 2022

The Company will be applying for quotation of the Escrowed Shares upon their date of release, in accordance with the ASX Listing Rules.

Following the release of the Escrowed Shares, the remaining shares held in the Company that are subject to either ASX imposed mandatory escrow arrangements or voluntary escrow arrangements are set out below.

ASX Mandatory Escrow

Number of Shares	Release Date
15,610,470	26 November 2023

Number of Options	Release Date
12,000,000	26 November 2023

Voluntary Escrow

Number of Shares	Release Date
25,168,121	26 November 2022

This announcement was approved by the Company's Managing Director, John Barrington, on behalf of the Artrya Board.

For further information please contact:

Investor Enquiries:

John Barrington
Artrya Limited
+61 419 850 502
investors@artrya.com

Media Enquiries:

Felicity Heath
Daymark
+61 457 196 603
felicity.heath@daymark.com.au

About Artrya

Based in Perth, Western Australia, Artrya was founded in 2018 and commenced operations in early 2019. Artrya Ltd is listed on the Australian Securities Exchange (ASX: AYA).

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of a patient at risk. The Company has developed deep learning algorithms that will allow for the prediction and prevention of acute coronary events.

For more information, see www.artrya.com